Form 4: Alkermes EVP Sells Shares After Option Exercise

Alkermes' EVP of R&D and Chief Medical Officer, Craig C. Hopkinson, exercised stock options and subsequently sold 3,748 ordinary shares for a profit.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer of Alkermes plc. (ALKS), executed a transaction on December 3, 2025.
• The transaction involved the exercise of 3,748 employee stock options at an exercise price of $19.34 per share.
• Immediately following the option exercise, 3,748 ordinary shares were sold at a weighted average price of $30.0019 per share.
• The sales occurred in multiple transactions at prices ranging from $30.00 to $30.03 per share.
• Both the option exercise and the subsequent sale were conducted under a Rule 10b5-1 trading plan established on March 14, 2025.
• Following these transactions, Hopkinson directly beneficially owns 65,740 ordinary shares and 36,356 employee stock options.

Sentiment

Score: 5

Explanation: Neutral. The filing reports a routine, pre-planned insider transaction (option exercise and sale) which is neither inherently positive nor negative for the company's operational performance or future prospects, though it represents a profit for the executive.

Positives

• The reporting person realized a profit from the option exercise and subsequent sale, indicating a gain on their equity compensation.

Negatives

• The sale of shares by a key executive reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor dilution from option exercise, but overall impact is negligible given the small number of shares relative to total outstanding.
• Executive: Realized a profit from equity compensation.

Key Dates

Recommendation

The Form 4 details a pre-planned insider transaction involving the exercise of stock options and subsequent sale of shares. This is a routine event related to executive compensation and does not provide new information that would fundamentally alter the investment thesis for Alkermes plc. Therefore, a 'hold' recommendation is maintained, pending further operational or strategic updates.

Keywords

Alkermes, ALKS, insider trading, Form 4, stock option, share sale, executive compensation, Craig C. Hopkinson, Rule 10b5-1